Table 1.
TKI | Axitinib (nM) | Tivozanib (nM) | Sunitinib (nM) | Pazopanib (nM) |
---|---|---|---|---|
Reference | Hu-Lowe (2008) | Nakamura et al. (2006) | Chow and Eckhardt (2007) | Kumar et al. (2009) |
VEGFR-1 | ND | 30 | 21 | 7 |
VEGFR-2 | 0.2 | 6.5 | 34 | 15 |
VEGFR-3 | ND | 15 | 3 | 2 |
PDGFR-β | 1.6 | 49 | 75 | 215 |
c-Kit | 1.7 | 78 | 40 | 48 |
FGFR-1 | ND | 530 | 437 | 80 |
IC50, inhibitory concentration 50%; TKI, tyrosine kinase inhibitor; ND, not done.